Skip to main content

Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies

European Journal of Drug Metabolism and Pharmacokinetics volume 33, pages 191–198 (2008)Cite this article

Summary

The plasma concentration of micafungin (MCFG) after intravenous infusion of MCFG at 150 or 300 mg/day over 1 hour to 49 patients with hematologic malignancies were determined, and the relationship between the plasma concentrations and the patients’ laboratory parameters of liver and kidney function was analyzed. Plasma samples were obtained at the end of the initial administration of MCFG, 5 to 6 hours after the start of the initial administration, immediately before the second dosing, immediately before the fourth dosing, and the end of the fourth dosing. The plasma concentration of MCFG was measured by high performance liquid chromatography. The plasma concentration of MCFG was correlated with the doses of MCFG per kilogram body weight. The peak concentration after the initial administration was 3.8 times higher than the trough level after the initial administration. The steadystate peak and trough levels were 1.4–1.5 times higher than those after the initial administration. There was no correlation between the laboratory parameters of liver/kidney function and the dose-normalized plasma concentration of MCFG. These results suggest that MCFG can be administered safely to patients with liver or kidney dysfunction without adjusting the dose.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Comely O.A., Ullmann A.J., Karthaus M. (2003): Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood, 101, 3365–3372.

    Article  Google Scholar 

  2. Kohno S., Yamaguchi H. (2002): Overview of micafungin (MCFG). Jap. J. Chemother., 50(S−1), 1–7.

    CAS  Google Scholar 

  3. Ikeda F., Otomo K., Nakai T., Morishita Y., Maki K., Tawara S., Mutoh, S., Matsumoto. F., Kuwahara, S. (2002): In vitro activity of a new lipopeptide antifungal agent, micafungin against a variety of clinically important fungi. Jap. J. Chemother., 50(S−1), 8–19.

    CAS  Google Scholar 

  4. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., Walsh T.J.; National Institute of Allergy and infectious Diseases Mycoses Study Group. (2004): Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis., 39, 1407–1416.

    Article  PubMed  Google Scholar 

  5. Ishikawa T., Takata T., Tomoyose T., Masuda M., Nakachi S., Koga S., Tsukada J., Matsuura A., Utsunomiya A., Saburi Y., Tamura K. (2006): The efficacy of micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents. Jap. J. Chemother., 54, 125–128.

    Google Scholar 

  6. Yanada M., Kiyoi H., Murata M., Suzuki M., Iwai M., Yokozawa T., Baba H., Emi N., Naoe T. (2006): Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern. Med., 45, 259–264.

    Article  PubMed  Google Scholar 

  7. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., Niki Y., Ikemoto H. (2004): A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis., 36, 372–379.

    Article  CAS  PubMed  Google Scholar 

  8. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., Lipton J., Jacobs P., Jansen van Rensburg J.H., Rex J.H., Lau W., Facklam D., Buell D.N. (2005): International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis., 24, 654–661.

    Article  CAS  PubMed  Google Scholar 

  9. Ruhnke M. Kuse E., Chetchotisakd P., da Cunha C.A., Diekmann-Berndt H. (2005): Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. Program, 228 Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. (Abstract. No.M-722c).

  10. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., Sekhon J.S., Freire A., Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A., Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky-Zeichner L., Lortholary O., Koblinger S., Diekmann-Berndt H., Comely O.A. (2007): Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 369(9572), 1519–27.

    Article  CAS  PubMed  Google Scholar 

  11. Yamato Y., Kaneko H., Tanimoto K., Katashima M., Ishibashi K., Kawamura A., Terakawa M., Kagayama A. (2002): Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jap. J. Chemother., 50(S−1), 68–73.

    CAS  Google Scholar 

  12. Azuma J., Nakahara K., Kagayama A., Kajiho T., Kawamura A., Suematsu H. Mukai T. (2002): Phase I study of micafungin. Jap. J. Chemother., 50(S−1) 104–147.

    Google Scholar 

  13. Azuma J., Nakahara K., Kagayama A., Okuma T., Kawamura A., Mukai T. (2002): Pharmacokinetic study of micafungin. Jap. J. Chemother., 50(S−1), 155–184.

    Google Scholar 

  14. Azuma J., Nakahara K., Kagayama A., Fujiwara S., Kawamura A., Mukai T. (2002): Pharmacokinetic study of micafungin in elderly subjects. Jap. J. Chemother., 50(S−1), 148–154.

    Google Scholar 

  15. Tabata K., Katashima M., Kawamura A., Tanigawara Y., Sunagawa K. (2006): Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol. Pharm. Bull., 29, 1706–1711.

    Article  CAS  PubMed  Google Scholar 

  16. Shimoeda S., Ohta S., Kobayashi H., Saitou H., Kubota A., Yamato S., Shimada K., Sasaki M., Kawano K. (2005): Analysis of the blood level of micafungin involving patients with hematological diseases: New findings regarding combination therapy with tacrolimus. Biol. Pharm. Bull. 28, 477–480.

    Article  CAS  PubMed  Google Scholar 

  17. Tabata K., Katashima M., Kawamura A., Kaibara A., Tanigawara Y. (2006): Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infection. Drug Metab. Pharmacokin., 21, 324–331.

    Article  CAS  Google Scholar 

  18. Yamato Y., Kaneko H., Hashimoto T., Katashima M., Ishibashi K. Kawamura A., Terakawa M., Kagayama A. (2002): Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jap. J. Chemother., 50(S−1), 74–79.

    CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Hematology, Japanese Red Cross Medical Center, 4-1-22, Hiroo, Shibuya, 150-8935, Tokyo, Japan

    Yasunori Nakagawa & Kenshi Suzuki

  2. Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan

    Yoko Ichii, Yasuhiro Saeki & Masanobu Kodama

  3. Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan

    Satoshi Kishino

Authors
  1. Yasunori Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoko Ichii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiro Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanobu Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Kishino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nakagawa, Y., Ichii, Y., Saeki, Y. et al. Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies. Eur. J. Drug Metabol. Pharmacokinet. 33, 191–198 (2008). https://doi.org/10.1007/BF03191118

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03191118

Key words

  • Micafungin
  • fungal infection
  • febrile neutropenia
  • pharmacokinetics